EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma

Patricia L Theard, Amanda J Linke, Nancy E Sealover, Brianna R Daley, Johnny Yang, Katherine Cox, Robert L Kortum iD

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Patricia L Theard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Acrylamides, Aniline Compounds. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, DOD Peer Reviewed Cancer Research Program, Office of Extramural Research, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Son of sevenless 1 and 2 (SOS1 and SOS2) are RAS guanine nucleotide exchange factors (RasGEFs) that mediate physiologic and pathologic receptor tyrosine kinase (RTK)‐dependent RAS activation. Here, we show that SOS2 modulates the threshold of epidermal growth factor receptor (EGFR) signaling to regulate the efficacy of and resistance to the EGFR tyrosine kinase inhibitor (EGFR‐TKI) osimertinib in lung adenocarcinoma (LUAD). SOS2 deletion ( SOS2 KO ) sensitized EGFR ‐mutated cells to perturbations in EGFR signaling caused by reduced serum and/or osimertinib treatment to inhibit phosphatidylinositol 3‐kinase (PI3K)/AKT pathway activation, oncogenic transformation, and survival. Bypassing RTK reactivation of PI3K/AKT signaling represents a common resistance mechanism to EGFR‐TKIs; SOS2 KO reduced PI3K/AKT reactivation to limit osimertinib resistance. In a forced HGF/MET‐driven bypass model, SOS2 KO inhibited hepatocyte growth factor (HGF)‐stimulated PI3K signaling to block HGF‐driven osimertinib resistance. Using a long‐term in situ resistance assay, most osimertinib‐resistant cultures exhibited a hybrid epithelial/mesenchymal phenotype associated with reactivated RTK/AKT signaling. In contrast, RTK/AKT‐dependent osimertinib resistance was markedly reduced by SOS2 deletion; the few SOS2 KO cultures that became osimertinib resistant primarily underwent non‐RTK‐dependent epithelial–mesenchymal transition (EMT). Since bypassing RTK reactivation and/or tertiary EGFR mutations represent most osimertinib‐resistant cancers, these data suggest that targeting proximal RTK signaling, here exemplified by SOS2 deletion, has the potential to delay the development osimertinib resistance and enhance overall clinical responses for patients with EGFR ‐mutated LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungAcrylamidesAniline CompoundsIndolesPyrimidinesHumansProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesDrug Resistance, NeoplasmErbB ReceptorsReceptor Protein-Tyrosine KinasesMutationProtein Kinase Inhibitors

Stichwörter der Autor:innen

EGFR-TKIPI3KRASSOS2acquired resistanceosimertinib

Substanzen

osimertinibProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesErbB ReceptorsReceptor Protein-Tyrosine KinasesProtein Kinase InhibitorsEGFR protein, humanAcrylamidesAniline CompoundsIndoles

Autor:innen und Institutionen

  • Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

ORCID-Profile: Robert L Kortum

Förderung

  • NCI NIH HHS
  • DOD Peer Reviewed Cancer Research Program
  • Office of Extramural Research, National Institutes of Health

Zitieren

APA

Theard, P. L., Linke, A. J., Sealover, N. E., Daley, B. R., Yang, J., Cox, K., & Kortum, R. L. (2024). SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.13564

Vancouver

Theard PL, Linke AJ, Sealover NE, Daley BR, Yang J, Cox K, et al. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma. Molecular Oncology. 2024. doi:10.1002/1878-0261.13564

BibTeX
@article{Theard2024,
  author = {Theard, Patricia L and Linke, Amanda J and Sealover, Nancy E and Daley, Brianna R and Yang, Johnny and Cox, Katherine and Kortum, Robert L},
  title = {SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13564}
}
Kostenlos starten →